CS585 Demonstrates Favorable Selectivity and Sustained <i>In Vivo</i> Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists

Livia Stanger(University of Michigan), Michael Holinstat(Thomas Jefferson University), Björn Dahlöf(Sahlgrenska University Hospital), Devin Gilmore(University of Michigan), Sylviane Lambert(University of Michigan), Pooja Yalavarthi(University of Michigan), Niklas Bergh(Sahlgrenska University Hospital), Andrew Rickenberg(University of Michigan), Krista Goerger(University of Michigan)

Blood

November 2, 2023

10.1182/blood-2023-186300

Cited by 0

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

|The Lancet|2010|518

An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis

|Cell|2024|102